Lantheus Completes Acquisition of Life Molecular Imaging. Please see the press release to learn more.


Latest Press Releases

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

June 13, 2022

Read More at Our Investor Site

Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

June 13, 2022

Read More at Our Investor Site

Additional Resources


Receive Email Alerts

Media Contact

Melissa Downs

Senior Director, Corporate Communications
646-975-2533

media@lantheus.com

Investors

Mark Kinarney

Vice President, Investor Relations
978-671-8842

ir@lantheus.com